INTRODUCTION
Bevacizumab (Avastin; F. Hoffmann-La Roche, Basel, Switzerland), a vascular endothelial growth factor-specific antibody, significantly prolonged progression-free survival (PFS) and overall survival (OS) when added to doublet chemotherapy in the Eastern Cooperative Oncology Group (ECOG) study E4599 and prolonged PFS in the Avastin in Lung (AVAiL) study. This approach is approved by the US Food and Drug Administration and European Medicines Agency for patients with advanced nonsquamous non-small-cell lung cancer (NSCLC) without hemoptysis. [1] [2] [3] The BR.21 trial demonstrated an OS benefit for the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor erlotinib (Tarceva; F. Hoffmann-La Roche) compared with placebo in second-and third-line
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advanced NSCLC, 4 leading to approval by the US Food and Drug Administration and European Medicines Agency. However, the long-term prognosis for patients with lung cancer remains disappointing, 5 and maintenance therapy, whereby further active treatment is administered to delay progression after successful tumor control with first-line chemotherapy, has been the subject of recent research.
Because bevacizumab and erlotinib target different molecular pathways involved in tumorigenesis (vascular endothelial growth factor and EGFR, respectively), a phase I/II trial examined their combined use in patients with previously treated NSCLC. No unexpected toxicities or pharmacokinetic interactions were observed between the two drugs at their recommended doses. 6 The combination demonstrated encouraging clinical activity in a randomized, phase II, secondline study, with a disease control rate of 85% and modest prolongation of PFS, although the prespecified primary end point of a clinically meaningful difference in PFS for bevacizumab/erlotinib versus chemotherapy (pemetrexed or docetaxel) was not achieved (hazard ratio [HR] , 0.72; 95% CI, 0.42 to 1.23). 7 More recently, the phase III Bevacizumab Plus Tarceva (BeTa) study in advanced NSCLC failed to meet its primary end point of improved OS with the addition of bevacizumab to second-line erlotinib but showed promising PFS benefit with the combination versus erlotinib alone (median, 3.4 v 1.7 months, respectively; HR, 0.62; 95% CI, 0.52 to 0.75). 8 Overall, these studies suggested good tolerability and promising antitumor activity for the erlotinib and bevacizumab combination, making it a logical regimen for evaluation as maintenance therapy in advanced NSCLC.
PATIENTS AND METHODS

Study Design
The Avastin Tarceva Lung Adenocarcinoma Study (ATLAS) was a phase III, multicenter, randomized, placebo-controlled trial conducted at 187 sites worldwide between January 10, 2006, and June 19, 2009 (ClinicalTrials.gov identifier: NCT00257608). The primary objective was to compare the PFS of patients with advanced NSCLC randomly assigned to bevacizumab/erlotinib versus bevacizumab/placebo after completion of four cycles of chemotherapy plus bevacizumab without disease progression or significant toxicity. Secondary objectives included safety and OS.
The study comprised two treatment phases, an open-label chemotherapy plus bevacizumab phase and a randomized, double-blind, placebo-controlled postchemotherapy phase (study design, Fig 1; CONSORT diagram, Fig 2) . The control regimen was based on results from E4599. 1 Six platinum-based chemotherapy options were permitted, at the choice of the investigators. No bevacizumab dose reductions were permitted. If an adverse event (AE) occurred that necessitated interruption of bevacizumab, the dose was to remain unchanged once treatment resumed, or the drug was discontinued. Erlotinib dose reductions in decrements of 50 mg per day and standard chemotherapy dose modifications were permitted for toxicity.
The study was conducted in accordance with Good Clinical Practice guidelines and was approved by the review board/local ethics committees at each participating center. All patients provided written informed consent.
Eligibility Criteria
Eligible patients were Ն 18 years of age, with histologically or cytologically confirmed NSCLC (stage IIIB with malignant pleural effusion or stage IV) or recurrent disease and an ECOG performance status of 0 or 1. Patients with a history of brain metastases were eligible provided their brain metastases had been treated and they did not require ongoing dexamethasone. Patients with squamous cell carcinoma were eligible provided their disease was extrathoracic or their intrathoracic disease comprised peripheral lesions only. Known EGFR mutation status was not required for inclusion and was not a stratification factor.
Random Assignment and Blinding
Patients eligible for the postchemotherapy phase were randomly assigned 1:1 to receive bevacizumab plus either erlotinib or placebo and were stratified by sex, smoking history (never v former/current), ECOG performance status (0 v Ն 1), and initial chemotherapy regimen. Random assignment was conducted centrally using a hierarchical dynamic random assignment scheme using an interactive voice response system provided by a third party (ClinPhone, Nottingham, United Kingdom) to ensure approximately equal sample sizes between the two treatment arms overall, within each stratification factor, and at each study site. The study sponsor, investigators, and patients were blinded to treatment assignment.
Procedures
Baseline information was collected, including brain imaging with computed tomography or magnetic resonance imaging, tumor assessment via (n = 363) (n = 126) (n = 237) (n = 168) (n = 38) (n = 31) (n = 7) (n = 364) (n = 124) (n = 240) (n = 158) (n = 48) (n = 34) (n = 6) Intent-to-treat efficacy population Bevacizumab-treated efficacy population Safety-evaluable randomly allocated patients RECIST (version 1.0), 9 vital signs, physical examination, and blood/urinary laboratory analyses. Tumor assessments were recorded at the end of cycles 2 and 4 (chemotherapy phase) and then every second cycle in the postchemotherapy phase (to cycle 12 and every four cycles thereafter) and at the study treatment termination visit (approximately 30 Ϯ 7 days after study treatment discontinuation). Disease progression was classified according to RECIST, 9 by investigator assessment.
AEs were recorded after every treatment cycle (chemotherapy and postchemotherapy phases) and up to 30 days after treatment termination and were mapped to the Medical Dictionary for Regulatory Activities terms and classified by grade according to the National Cancer Institute Common Terminology Criteria for Adverse Events (version 3.0).
Statistical Analyses
The primary end point was PFS in patients randomly assigned to bevacizumab/erlotinib versus bevacizumab/placebo in the postchemotherapy phase. PFS was defined as the length of time from random assignment until disease progression, assessed by RECIST, 9 or death from any cause (when this occurred within 30 days of stopping study treatment). Tumor measurements from the assessment before random assignment served as the baseline for determining progression.
Secondary efficacy end points included OS (time from random assignment to death) and safety. Exploratory efficacy analyses included the effects of baseline characteristics on PFS and OS.
PFS and OS were tested using a two-sided stratified log-rank test (stratified by all random assignment stratification factors except study site) with an overall ␣ ϭ .05 controlled by a fixed sequence approach.
10 Median PFS and OS were estimated using the Kaplan-Meier method, and the HR was estimated using a stratified Cox regression model. All analyses were conducted by the study statistician with input from the lead investigators. The primary population for the efficacy analyses included all patients randomly assigned during the postchemotherapy phase (intent-to-treat [ITT] population). A secondary efficacy population of bevacizumab-treated patients was also analyzed, defined as all enrolled patients who received at least one dose of bevacizumab during the chemotherapy phase. The primary safety analysis was in the postchemotherapy phase (ie, from the first dose of randomly assigned treatment until either 30 days after the final dose in the postchemotherapy phase or until the first dose of postprogression phase treatment). The safety-evaluable randomized (SER) population included all randomly assigned patients who received at least one complete or partial dose of bevacizumab/erlotinib or bevacizumab/ placebo. Data on AEs leading to treatment discontinuation, prespecified AEs of special interest (AESIs; ie, grade Ն 3 GI perforation, arterial thromboembolic events, proteinuria, congestive heart failure, and hypertension), and serious AEs (grade Ն 2 pulmonary hemorrhage and symptomatic CNS hemorrhage) were collected during the initial chemotherapy phase, the postchemotherapy phase, and for up to 30 days after discontinuation of study treatment. All other AEs were recorded during the postchemotherapy phase only.
The study had 78% power to detect an increase in PFS from 5.4 to 6.8 months (measured from random assignment) with a two-sided overall significance level of 5% (PFS HR of 0.79 or a 21% risk reduction in PFS). Assuming a 30% drop out of enrolled patients before random assignment, 1,150 patients were enrolled to ensure that at least 800 patients were observed and 638 post-random assignment PFS events had occurred. Two interim efficacy analyses were prospectively planned, to be performed at 33% and 67% of PFS events. At the second efficacy interim analysis (data cutoff July 18, 2008; 69% of PFS events had occurred), the study had met its primary end point of improved PFS, and therefore, this became the primary analysis, with any further analyses of PFS being considered exploratory. An additional exploratory analysis of efficacy and safety was conducted on data collected up to and including January 28, 2009, when the positive outcome of the study was announced and the study was unblinded. Furthermore, an additional OS data sweep was performed with a cutoff date of June 19, 2009. Given the potential for bias, additional updates for all efficacy analyses except OS were not conducted on data collected after July 18, 2008. Unless otherwise stated, the data presented here are for the primary data cutoff (July 18, 2008).
RESULTS
Patient Population
A total of 1,145 patients were enrolled onto the chemotherapy phase (Fig 2) from January 2006 to June 2009. At the time of the July 18, 2008, data cutoff, 743 patients (64.9%) had been randomly assigned into the postchemotherapy phase (ITT population) and 735 patients (64.2%) were in the SER population. Because accrual was not halted until after the data monitoring committee recommendation was received (Data Supplement), an additional 25 patients had been randomly assigned by the January 28, 2009, data cutoff; the resulting ITT population comprised 768 patients (67.1%) and the SER population comprised 760 patients (66.4%). Baseline characteristics for the ITT population were well balanced for all randomly assigned patients (Table 1) .
Efficacy
The median follow-up times for the bevacizumab/placebo and bevacizumab/erlotinib arms were 8.3 and 8.5 months (July 18, 2008, cutoff) and 14.1 and 14.6 months (January 28, 2009, cutoff), respectively. At the primary analysis cutoff, 237 patients (63.5%) in the bevacizumab/placebo arm and 202 patients (54.6%) in the bevacizumab/erlotinib arm had experienced a PFS event (disease progression or death). Median PFS times from time of random assignment were 3.7 and 4.8 months in the bevacizumab/placebo and bevacizumab/erlotinib arms, respectively. This difference was statistically significant for both the stratified (HR, 0.708; 95% CI, 0.580 to 0.864; log-rank P Ͻ .001; Fig 3) and unstratified analyses (HR, 0.683; 95% CI, 0.565 to 0.824; log-rank P Ͻ .001).
The median OS times from time of random assignment were 13.3 months in the bevacizumab/placebo arm and 14.4 months in the bevacizumab/erlotinib arm (stratified analysis: HR, 0.917; 95% CI, 0.698 to 1.205; P ϭ .5341; Fig 4) . Similar results were also obtained in the unstratified analysis (HR, 0.941; 95% CI, 0.726 to 1.220; 
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At the updated data analysis cutoff (January 28, 2009), median OS times from time of random assignment were 13.6 and 14.4 months in the bevacizumab/placebo and bevacizumab/erlotinib arms, respectively (HR, 0.904; 95% CI, 0.729 to 1.120; P ϭ .3534; Appendix Fig A1,  online only) . Final OS data from the June 19, 2009, cutoff are included in Appendix Figure A2 (online only).
The reduction in the risk of disease progression or death for clinically important subgroups was consistent with the overall treatment effect as showninFigure5.Posthocanalysisofoverallresponserateinthepostchemotherapy phase is included in the Data Supplement.
Biomarker analyses (cutoff July 18, 2008) found that patients whose tumors harbored an activating EGFR mutation (n ϭ 52) had a greater improvement in PFS with bevacizumab/erlotinib (n ϭ 27) versus bevacizumab/placebo (n ϭ 25; HR, 0.44; 95% CI, 0.22 to 0.86) compared with the wild-type subgroup (total, n ϭ 295; n ϭ 150 for bevacizumab/erlotinib and n ϭ 145 for bevacizumab/placebo; HR, 0.85; 95% CI, 0.64 to 1.13). OS results at the July 19, 2009, cutoff showed a similar difference in outcome by EGFR mutation status (HR, 0.46; 95% CI, 0.21 to 1.02 for the EGFR mutation-positive subgroup; and HR, 0.86; 95% CI, 0.65 to 1.15 for the EGFR wild-type subgroup).
Safety
Treatment exposure. At data cutoff (July 18, 2008) , in the postchemotherapy phase, 732 patients (98.5%) received at least one dose of bevacizumab (bevacizumab/placebo, n ϭ 365; bevacizumab/erlotinib, n ϭ 367), and 734 patients (98.8%) received erlotinib or placebo (bevacizumab/placebo, n ϭ 366; bevacizumab/erlotinib n ϭ 368). A total of 109 patients (29.2%) in the bevacizumab/placebo arm and 126 patients (34.1%) in the bevacizumab/erlotinib arm remained on bevacizumab, and 124 patients (33.5%) in the bevacizumab/erlotinib arm were still receiving erlotinib as of July 18, 2008. The median durations of postchemotherapy bevacizumab were 64 and 72 days in the bevacizumab/placebo and bevacizumab/erlotinib arms, respectively. The median durations of erlotinib and placebo were 85 and 78 days, respectively. More patients missed a dose or had a dose reduction of erlotinib/placebo in the bevacizumab/erlotinib arm than in the bevacizumab/placebo arm ( AEs. At the data cutoff (July 18, 2008) , during the postchemotherapy phase only, more AEs were reported in the bevacizumab/ erlotinib arm than in the bevacizumab/placebo arm ( Table 2) . Abbreviations: AESI, adverse event of special interest; ATE, arterial thromboembolic event; ILD, interstitial lung disease; RPLS, reversible posterior leukoencephalopathy syndrome; SER, safety-evaluable randomly assigned; VTE, venous thromboembolic event.
‫ء‬ Incidence of Ն 5% for all grades in at least one treatment arm. †Discontinuation of study drug in at least two patients in at least one study arm. ‡Of the nine patients with pulmonary hemorrhage, seven had adenocarcinoma and two had other histology.
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Prespecified AESIs were predominantly grade 1 or 2, and the incidence was similar between treatment arms, with the exception of rash, diarrhea, and infection, which were more common with bevacizumab/ erlotinib. No grade 3 or 4 interstitial lung disease-like events were reported in the bevacizumab/placebo arm, but three patients (0.8%) in the bevacizumab/erlotinib arm experienced a grade 3 interstitial lung disease-like event (after 15, 41, and 143 days of bevacizumab/ erlotinib treatment). Rash and diarrhea were the only grade 3 or 4 AEs reported at a Ն 5% higher incidence in the bevacizumab/erlotinib arm than the bevacizumab/placebo arm (rash: 6.8% v 0.5%, respectively; diarrhea: 9.8% v 1.9%, respectively). Six grade 5 AESIs were reported, two with bevacizumab/placebo (congestive heart failure and lobar pneumonia) and four with bevacizumab/erlotinib (cardiac arrest, n ϭ 2; cerebellar infarction, n ϭ 1; and deep vein thrombosis, n ϭ 1). One additional grade 5 event (GI perforation) was reported in the bevacizumab/erlotinib arm after the July 18, 2008, cutoff.
DISCUSSION
After four cycles of chemotherapy plus bevacizumab, the addition of erlotinib to maintenance bevacizumab significantly improved PFS in patients with advanced NSCLC. This PFS benefit was consistently observed in prespecified subgroups defined by stratification factors and other baseline characteristics. As expected after the results of other recent studies, 11-13 EGFR mutation status was strongly associated with exceptional PFS benefit from erlotinib in this study.
These results are comparable with recent data from other advanced NSCLC studies showing a significant PFS benefit after maintenance therapy.
2,3,14-18 In AVAiL, the addition of bevacizumab (7.5 or 15.0 mg/kg) to platinum-based doublet chemotherapy achieved a significant but modest PFS prolongation versus placebo (6.5 to 6.7 v 6.1 months, respectively; P Յ .03) when administered until disease progression in advanced nonsquamous NSCLC.
2, 3 The Sequential Tarceva in Unresectable NSCLC (SATURN) study reported significantly longer PFS and OS for patients receiving erlotinib maintenance versus placebo (median PFS, 12.3 v 11.1 weeks, respectively; P Ͻ .001; median OS, 12.0 v 11.0 months, respectively; P ϭ .0088), with the greatest benefit being observed in the EGFR mutation-positive subgroup (HR, 0.10; P Ͻ .001).
11,16 Both docetaxel and pemetrexed maintenance therapy demonstrated prolonged PFS versus waiting for second-line treatment, 14,15 whereas data from the AVAPERL study suggest that the addition of pemetrexed to bevacizumab maintenance therapy reduces the risk of progression compared with bevacizumab alone, adding up to 4 months in PFS benefit. 17 In addition, the PARAMOUNT study of continuation maintenance with pemetrexed after a cisplatin/pemetrexed first-line regimen found that maintenance pemetrexed significantly reduced the risk of progression (P Ͻ .001) 18 and prolonged survival by approximately 3 months versus placebo (P ϭ .02).
19
Examining the results of this study versus the SATURN study of erlotinib monotherapy in the maintenance setting, the PFS benefit was similar; median PFS in the erlotinib arm of SATURN was 2.8 months, 16 compared with 3.7 months (bevacizumab/placebo) and 4.8 months (bevacizumab/erlotinib) in ATLAS. In both studies, EGFR mutation-positive status was a strong predictor of increased PFS benefit with erlotinib.
The point estimate for OS HR in this study was only marginally in favor of the combination regimen (HR, 0.897; 95% CI, 0.740 to 1.087) and not statistically significant up to the last follow-up (June 19, 2009). It should be noted that the study was not powered to detect differences in OS, it was unblinded after the interim analysis, and further survival follow-up was not pursued based on the low likelihood of observing significant differences between arms. More than 50% of patients in each arm had subsequent second-line therapy; 41% of patients in each arm received second-line erlotinib, whereas 41% and 25% of patients in the bevacizumab/placebo and bevacizumab/erlotinib arms, respectively, received subsequent bevacizumab. This crossover highlights the difficulties of using OS as an end point for studies in advanced NSCLC, particularly for first-line studies where patients may go on to receive multiple additional lines of therapy. Although a significant OS benefit was observed in the E4599 study (12.3 months with chemotherapy/ bevacizumab v 10.3 months with chemotherapy alone; P ϭ .003), 1 no survival difference was seen between treatment arms in AVAiL where patients received gemcitabine/cisplatin plus bevacizumab (7.5 or 15 mg/kg) to progression or gemcitabine/cisplatin alone. 3 Other studies have also failed to convert a PFS benefit into an OS benefit in the maintenance 15 or second-line settings, 8 although the JMEN study reported a significant OS advantage with pemetrexed versus placebo in the overall (13.4 v 10.6 months, respectively; P ϭ .012) and nonsquamous populations (15.5 v 10.3 months, respectively; P ϭ .002).
14 The choice of end point is clearly an important factor in whether a study is positive or negative, and this has implications for future trials in NSCLC. It could be argued that PFS treatment effects should be much larger, in which case trials would not need to be sized to detect a survival difference (and a greater degree of crossover could be permitted). Alternatively, in unselected populations, OS could be used as the primary end point, although it is possible that larger treatment effects should also be considered for this end point.
Safety data during the chemotherapy phase of the study indicate an acceptable safety profile for bevacizumab in combination with a variety of chemotherapy regimens, with results similar to those reported in previous phase III trials. [1] [2] [3] During the postchemotherapy phase, the bevacizumab/erlotinib regimen was well tolerated, although toxicity was increased compared with the safety profile of either agent alone. [1] [2] [3] [4] In conclusion, ATLAS met its primary end point; maintenance treatment with bevacizumab/erlotinib improved PFS compared with bevacizumab maintenance alone. However, OS was not improved, and treatment with bevacizumab/erlotinib resulted in increased toxicity. Therefore, the results of this study do not provide enough evidence to support a new standard of care, particularly with regard to the benefit-risk profile of this regimen. 
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